Your browser is no longer supported. Please, upgrade your browser.
PTLA Portola Pharmaceuticals, Inc. daily Stock Chart
PTLA [NASD]
Portola Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-3.77 Insider Own0.80% Shs Outstand78.17M Perf Week0.45%
Market Cap1.42B Forward P/E- EPS next Y-2.15 Insider Trans0.00% Shs Float77.65M Perf Month0.45%
Income-281.30M PEG- EPS next Q-0.66 Inst Own- Short Float16.68% Perf Quarter178.24%
Sales120.90M P/S11.71 EPS this Y23.40% Inst Trans-1.49% Short Ratio2.96 Perf Half Y-24.50%
Book/sh0.92 P/B19.60 EPS next Y27.50% ROA-55.30% Target Price19.83 Perf Year-31.05%
Cash/sh4.62 P/C3.90 EPS next 5Y- ROE-270.90% 52W Range5.31 - 31.73 Perf YTD-24.50%
Dividend- P/FCF- EPS past 5Y-4.90% ROI- 52W High-43.18% Beta2.30
Dividend %- Quick Ratio4.80 Sales past 5Y64.70% Gross Margin78.90% 52W Low239.55% ATR0.05
Employees408 Current Ratio4.90 Sales Q/Q18.90% Oper. Margin- RSI (14)93.63 Volatility0.20% 0.22%
OptionableNo Debt/Eq4.79 EPS Q/Q24.50% Profit Margin- Rel Volume1.91 Prev Close18.03
ShortableNo LT Debt/Eq4.67 EarningsMay 11 AMC Payout- Avg Volume4.38M Price18.03
Recom2.70 SMA200.46% SMA5012.89% SMA200-3.16% Volume0 Change0.00%
Apr-23-20Initiated RBC Capital Mkts Outperform $20
Jan-10-20Downgrade Oppenheimer Outperform → Perform
Nov-08-19Initiated Goldman Neutral $35
Aug-05-19Resumed Credit Suisse Neutral $35
Jul-10-19Resumed Credit Suisse Neutral
Aug-27-18Upgrade Credit Suisse Underperform → Neutral
Aug-10-18Downgrade Credit Suisse Neutral → Underperform
Mar-01-18Downgrade Morgan Stanley Overweight → Equal-Weight
Dec-01-17Initiated Goldman Buy $75
Aug-24-17Upgrade Credit Suisse Neutral → Outperform
Jun-26-17Reiterated Morgan Stanley Overweight $50 → $70
Jun-26-17Reiterated Citigroup Buy $51 → $78
Feb-24-17Upgrade Oppenheimer Perform → Outperform
Jan-03-17Upgrade Citigroup Neutral → Buy
Dec-27-16Reiterated Credit Suisse Outperform $20 → $29
Aug-19-16Downgrade Citigroup Buy → Neutral
May-31-16Downgrade Credit Suisse Outperform → Neutral $33 → $30
Mar-28-16Reiterated Credit Suisse Outperform $47 → $34
Mar-28-16Downgrade Goldman Buy → Neutral $65 → $30
Dec-18-15Initiated Goldman Buy
Jun-24-20 10:36AM  
Jun-17-20 11:30PM  
Jun-05-20 05:24PM  
Jun-04-20 10:15AM  
May-28-20 10:11AM  
May-26-20 11:00AM  
May-22-20 01:00PM  
May-21-20 02:10PM  
May-19-20 12:15PM  
10:14AM  
May-18-20 04:02PM  
02:00PM  
May-16-20 03:00PM  
May-15-20 06:00PM  
04:48PM  
02:39PM  
02:35PM  
01:20PM  
May-14-20 05:30PM  
08:00AM  
May-13-20 12:40PM  
May-12-20 05:07PM  
09:51AM  
May-11-20 03:30PM  
01:40PM  
10:05AM  
08:00AM  
May-09-20 08:30AM  
May-08-20 12:33PM  
May-07-20 11:40AM  
10:40AM  
May-06-20 01:39PM  
09:46AM  
09:45AM  
May-05-20 11:35PM  
08:02PM  
04:58PM  
04:02PM  
03:10PM  
02:23PM  
01:00PM  
12:42PM  
12:39PM  
12:30PM  
11:13AM  
10:50AM  
10:48AM  
10:42AM  
09:36AM  
May-01-20 04:23PM  
Apr-23-20 04:21PM  
Apr-08-20 08:41PM  
Apr-07-20 08:00AM  
Apr-01-20 04:02PM  
Mar-18-20 04:11PM  
Mar-17-20 07:21PM  
Mar-16-20 10:45AM  
10:00AM  
08:05AM  
Mar-15-20 10:50PM  
05:30PM  
Mar-14-20 12:00PM  
Mar-13-20 10:50PM  
04:45PM  
01:45PM  
09:59AM  
Mar-12-20 11:00AM  
10:50AM  
10:45AM  
Mar-11-20 10:50PM  
05:30PM  
04:05PM  
03:45PM  
03:07PM  
10:50AM  
09:58AM  
Mar-10-20 10:50PM  
02:40PM  
02:10PM  
10:50AM  
Mar-09-20 10:50PM  
06:04PM  
03:40PM  
03:00PM  
02:00PM  
10:55AM  
10:45AM  
09:57AM  
09:37AM  
Mar-08-20 05:15PM  
01:00PM  
10:40AM  
Mar-06-20 10:50PM  
11:50AM  
11:06AM  
Mar-05-20 05:10PM  
05:00PM  
03:25PM  
10:00AM  
08:30AM  
Portola Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes novel therapeutics in the areas of thrombosis, and other hematologic disorders and inflammation in Europe and the United States. Its lead product Andexxa, an antidote for the treatment of rivaroxaban and apixaban under the Ondexxya Brand. The company offers Bevyxxa (betrixaban), an oral, once-daily Factor Xa inhibitor for the prevention of venous thromboembolism in adult patients for an acute medical illness. It also develops cerdulatinib, an investigational oral, dual spleen tyrosine kinase, and janus kinases inhibitor for the treatment of hematologic cancers; and Syk inhibitors. Portola Pharmaceuticals, Inc. has collaboration agreements with Bristol-Myers Squibb; Pfizer Inc.; Daiichi Sankyo, Inc.; Bayer Pharma, AG; Takeda, Ora, Inc.; Astellas Pharma Inc.; and Janssen Pharmaceuticals, Inc. The company was founded in 2003 and is headquartered in South San Francisco, California. As of July 1, 2020, Portola Pharmaceuticals, Inc. operates as a subsidiary of Alexion Pharmaceuticals, Inc.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
RENTON HOLLINGSDirectorNov 01Option Exercise9.005,00045,00018,194Nov 04 07:32 PM
RENTON HOLLINGSDirectorNov 01Sale30.005,000150,00013,194Nov 04 07:32 PM
RENTON HOLLINGSDirectorAug 08Option Exercise9.005,00045,00018,194Aug 09 06:51 PM
RENTON HOLLINGSDirectorAug 08Sale30.005,000150,00013,194Aug 09 06:51 PM